India Pharma Outlook | Tuesday, 15 July 2025
Baxdrostat at two doses (2 mg and 1 mg) showed a statistically significant and clinically relevant reduction in mean sitting systolic blood pressure (SBP) at 12 weeks when compared with placebo, according to positive high-level data from the BaxHTN Phase III trial.
Additionally, all secondary endpoints were effectively satisfied by the trial. In addition to conventional therapy, patients with uncontrolled or treatment-resistant hypertension were given either baxdrostat or a placebo. Baxdrostat has a favorable safety profile and was generally well tolerated. Hypertension is being lived with by 1.3 billion people worldwide. When uncontrolled, a higher risk of heart attack, stroke, heart failure, and kidney disease can be led to by hypertension. In the US, it is estimated that blood pressure is not under control by approximately 50% of hypertensive patients who are on multiple treatments.
Dr. Bryan Williams, Chair of Medicine at University College London, primary investigator, said: “Many people continue to struggle with high blood pressure that is hard to control, even when taking multiple medications. The highly promising BaxHTN Phase III results show that once-daily baxdrostat on top of standard of care can meaningfully lower systolic blood pressure and offer a potential new treatment approach for controlling hypertension, the leading risk factor for cardiovascular disease.”
Also Read: VarmX Secures FDA Approval for Phase 3 Trial of VMX-C001
Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, said: “We are very excited with the BaxHTN Phase III results, which show statistically significant and clinically meaningful reductions in systolic blood pressure. These findings provide compelling evidence of baxdrostat’s potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades.”
